January/February #151 : HIV Treatment Guidelines Revised Again - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Out On A Limb

Your Money or Your Life




The Sinus Monologues

Expert Opinion

Earlier HIV Meds?

HIV Treatment Guidelines Revised Again

Tea Time

Check My Meds

HIV-Med Pipeline Update

Complaint Department

Med Alert

Share the Wealth

Decreased Counts

Energy Savers

Sexual Healing

Make Those Doc Visits Count




Seeking Sisterhood

Forgotten No More

Is AIDS a Riot?

This Boy’s Life

Resistance Is Futile




Editor's Letter - Jan/Feb 2009

Letters - Jan/Feb 2009

Bear With Him

NAPWA/TAEP HIV/AIDS POLICY REPORT - Jan/Feb 2009



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

January / February 2009


HIV Treatment Guidelines Revised Again

by Laura Whitehorn

In early November, the U.S. Department of Health and Human Services (DHHS) issued changes to its guidelines for HIV treatment. Some of the major changes pertain to people just starting HIV meds, including these three notable shifts:

1. Prezista (darunavir), boosted with Norvir (ritonavir), is now listed among the “preferred” choices to include in a first HIV regimen.

2. Once-daily Kaletra (lopinavir plus ritonavir) joins the twice-daily dose on the preferred first-regimen list.

3. Epzicom (abacavir plus lamivudine) has been switched from preferred to “alternative” for those just starting HIV meds. The change reflects concerns about abacavir’s effect on heart health, as well as its reduced effectiveness for people beginning meds with high viral loads. For details, search “DHHS Major Updates” at poz.com.

Search: Prezista, Kaletra, Epzicom, Department of Health and Human Services


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         

[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    fokisi
    Long Beach
    California


    juliar33
    brooklyn
    New York


    pevans
    San Francisco
    California


    HOTROD2010
    houston
    Texas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you enjoy books with HIV-positive characters?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.